TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Adherence to ART - Objective (Viral Load Test Results <400 Copies/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Undetectable HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Summed mass of GH over 10 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence-adjusted bias adjusted kappa (PABAK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in serum phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Euro QoL 5 Dimensions Quality of Life Instrument (EQ-5D) Descriptive Systems Summary Index Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ-5D Visual Analog Scale (VAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the plasma concentration - to time = infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects achieving seroprotection and seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute Change in Non-inflammatory Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects Who Have at Least a 2 Grade Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects With Two Grade Reduction From Baseline and Achieving Clear or Almost Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six Minute Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Physical Activity Scale for Persons with Physical Disabilities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Operation-related neurological motor deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in ETC score before and after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target alveolar minute volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intensity of Low Back Pain (LBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Compliance level
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention level
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bladder leakage and symptoms of overactive bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diabetes level or severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Obesity level or severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of occurrence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of each of the adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Causality of each of the adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: glucose-c peptide release test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Motor block-interval assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Share of students that have been or are pregnant and/or have dropped out of school
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Share of students with the accurate belief that older partners have the highest risk of HIV compared to younger partners
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of aggregation in platelet rich plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in cold-induced non-shivering thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulins (G and M) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with undetectable RNA-HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Resolution of Achilles Tendon Enthesitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total Number of Central Line Associated Blood Stream Infections (CLABSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in plasma AGEs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in urinary AGEs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in plasma sRAGE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Alcohol Demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Remission (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pregnancy Rate (Pearl Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants Who Experience One or More Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinue Treatment Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Level of Patient Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients reporting full body skin examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Post-operative lens position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Insulin Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to the Maximum Concentration (Tmax) of Nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density t-score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep Molecular Response MR4.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 seroincidence
Endpoint domain: Mortality/survival
Primary endpoint: HSV2 seroprevalence
Endpoint domain: Mortality/survival
Primary endpoint: Change in Time Spent With Audiologist
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical improvement as shown by PaO2/FiO2>200
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first event of composite endpoint (doubling of serum creatinine, ESRD, or death)
Endpoint domain: Mortality/survival
Primary endpoint: incidence density of EV71-associated diseases
Endpoint domain: Mortality/survival
Primary endpoint: Gracely Pain Scale (GPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Treg Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Children's Emotional Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: segmentation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function over time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: average proportion of PEG-IFN and ribavirin doses received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of moderate-to-severe depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC0-last (Area under the curve from time 0 to the last time with quantifiable concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf (Area under the curve from time 0 to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment severity classification
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pCR Rate After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Residual Cancer Burden (RCB) by Symmans Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Peripheral anterior synechiae formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: IOP elevation >21 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Development of acute angle closure event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Tumor Hypoxia Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Biomarkers Expressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disposition index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hematologic Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: survival until discharge from the hospital
Endpoint domain: Mortality/survival
Primary endpoint: Weight Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leisure-time Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Caretaker Feeding Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Occurrence of a Dry SD-OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stage in Wagner's classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time to the development of low cardiac output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Annualized Bleeding Rate (TABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 2 years survival
Endpoint domain: Mortality/survival
Primary endpoint: 2 hours postprandial blood glucose (2-hr PPBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Spinal Cord Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Imaging Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate Defined as Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate Defined as Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Delirium Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life using King's Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 3-day frequency volume chart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour pad weigh test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alpha waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Theta waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Integrated HIV proviral DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intubation rate on 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time-to-exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise-induced Body Temperature Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in suicide ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in LVEF measured by cardiac MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of device-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Quantity of Opioids Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Exercise tolerance in meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self reported smoking status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of GSK1322322 formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of body weight on pharmacokinetics of GSK1322322
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revision surgery success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change in disability associated with chronic migraine disorder
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in headache impact test scores (HIT-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in health related quality of life associated with chronic migraine disorder
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in global cognitive functioning (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in global cognitive functioning (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in EF domain of IIEF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: distant disease-free survival (dDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Self-management Skills
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Survival of newly-diagnosed HIV-infected patients at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Adherence to the pathway
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage Change in Sputum Neutrophil Extracellular Traps (NETs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neck range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG activation patterns for SCM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle thickness & stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Efficacy Endpoint of Biopsy-proven Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function Assessed by Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: NDI Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete great toenail clearance or fungal-clear growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Negative fungal culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Coagulation Zone Diameter-Short Axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation Zone Diameter-Long Axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coagulation Zone Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak oxygen uptake (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Post-baseline Suicide Risk
Endpoint domain: Adverse events/effects
Primary endpoint: Drug exposure (Area under the curve) of lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healing time for leg ulcer and/or diabetes related foot ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of venous thrombo-embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of decrease of tattoos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Volume of Colloid Solution Required Intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean (SD) Maximum Observed Concentration (Cmax) of Eribulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean (SD) Area Under Concentration Time Curve From Zero to Infinity (AUC 0-oo) of Eribulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Other Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Sacral pressure injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients With Decline in Serum CA 15-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Achieved a Complete or Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Kaplan Meier Estimate of Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Acceptability of MBSR
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accessibility of MBSR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Y-BOCS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of siblings contacting the study team
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Ankle Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Function & Activity Limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) Through Day 35
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Resulting in Study Intervention Discontinuation Through Day 35
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events Through Day 35
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Progressed to Moderate or Severe Disease or Higher Based on the Gates MRI Ordinal Scale Through Day 28
Endpoint domain: Physiological/clinical
Primary endpoint: Maximum tolerated daily dose of melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients developing hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distinction between follicular adenoma and follicular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in OAB symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major structural defects in live born infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Confirmed Atrial Fibrillation (AF) Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-reported ART medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration versus time curve (AUC) 0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Global cognition-Hong Kong Montreal Cognitive Assessment (HK-MoCA) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pharmacoeconomics endpoint
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Antitumour activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Local or remote relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increase in parental knowledge regarding temperature definition for fever
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum concentration (Cmax) in plasma for BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC(0-T)) in plasma for BMS-986165
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes